Clinical PhII Study: Investigation for safety and efficacy of bendamustine and rituximab, B-R combination therapy for the patients of recurrent and/or refractory low-grade B cell lymphoma or mantle cell lymphoma previously treated with one or two regimen including rituximab

Trial Profile

Clinical PhII Study: Investigation for safety and efficacy of bendamustine and rituximab, B-R combination therapy for the patients of recurrent and/or refractory low-grade B cell lymphoma or mantle cell lymphoma previously treated with one or two regimen including rituximab

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms BRB
  • Most Recent Events

    • 07 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 22 May 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 24 May 2012 Planned End Date changed to 1 Mar 2018 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top